Cargando…

A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence

BACKGROUND: There is an unmet need for non-medication approaches to illicit opioid discontinuation and relapse prevention. The NET (NeuroElectric Therapy) Device is a non-invasive, battery-operated, portable, re-useable device designed to deliver bilateral transcranial transcutaneous alternating cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenwald, Mark K., Ghosh, Samiran, Winston, Joe R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593273/
https://www.ncbi.nlm.nih.gov/pubmed/36303593
http://dx.doi.org/10.1016/j.conctc.2022.101018
_version_ 1784815124144455680
author Greenwald, Mark K.
Ghosh, Samiran
Winston, Joe R.
author_facet Greenwald, Mark K.
Ghosh, Samiran
Winston, Joe R.
author_sort Greenwald, Mark K.
collection PubMed
description BACKGROUND: There is an unmet need for non-medication approaches to illicit opioid discontinuation and relapse prevention. The NET (NeuroElectric Therapy) Device is a non-invasive, battery-operated, portable, re-useable device designed to deliver bilateral transcranial transcutaneous alternating current electrical stimulation, and is intended to treat opioid use disorder (OUD) without medication. The device is a CE-marked Class IIa, non-significant risk, investigational medical device. OBJECTIVE: This prospective trial (NRC021) tests the hypothesis that the NET Device provides safe and effective neurostimulation treatment for persons with OUD who express a desire to be opioid abstinent without medications for opioid use disorder (MOUD). METHODS: NRC021 is a randomized, parallel-group, sham-controlled, quintuple-blinded, single-site study. Persons with OUD entering a residential treatment facility for opioid detoxification are assigned to active or sham treatment (n = 50/group). Group assignment is stratified on presence of any current non-opioid substance use disorder and by sex. The biostatistician maintains the blinding so that the study sponsor, principal investigator, research assistants, treatment staff, and participants remain blinded. Following discharge from the inpatient facility, participants are assessed once weekly over 12 weeks for substance use (using timeline followback interview and video assessment of observed oral fluid sample provision and testing). The primary efficacy endpoint is each participant's overall percentage of weekly abstinence from illicit opioid use without use of MOUD. The secondary efficacy endpoint is each participant's percentage of non-opioid drug-free weeks. Safety outcomes are also measured. CONCLUSION: NRC021 is designed to assess the efficacy of a novel non-medication treatment for OUD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov with the identifier NCT04916600.
format Online
Article
Text
id pubmed-9593273
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95932732022-10-26 A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence Greenwald, Mark K. Ghosh, Samiran Winston, Joe R. Contemp Clin Trials Commun Article BACKGROUND: There is an unmet need for non-medication approaches to illicit opioid discontinuation and relapse prevention. The NET (NeuroElectric Therapy) Device is a non-invasive, battery-operated, portable, re-useable device designed to deliver bilateral transcranial transcutaneous alternating current electrical stimulation, and is intended to treat opioid use disorder (OUD) without medication. The device is a CE-marked Class IIa, non-significant risk, investigational medical device. OBJECTIVE: This prospective trial (NRC021) tests the hypothesis that the NET Device provides safe and effective neurostimulation treatment for persons with OUD who express a desire to be opioid abstinent without medications for opioid use disorder (MOUD). METHODS: NRC021 is a randomized, parallel-group, sham-controlled, quintuple-blinded, single-site study. Persons with OUD entering a residential treatment facility for opioid detoxification are assigned to active or sham treatment (n = 50/group). Group assignment is stratified on presence of any current non-opioid substance use disorder and by sex. The biostatistician maintains the blinding so that the study sponsor, principal investigator, research assistants, treatment staff, and participants remain blinded. Following discharge from the inpatient facility, participants are assessed once weekly over 12 weeks for substance use (using timeline followback interview and video assessment of observed oral fluid sample provision and testing). The primary efficacy endpoint is each participant's overall percentage of weekly abstinence from illicit opioid use without use of MOUD. The secondary efficacy endpoint is each participant's percentage of non-opioid drug-free weeks. Safety outcomes are also measured. CONCLUSION: NRC021 is designed to assess the efficacy of a novel non-medication treatment for OUD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov with the identifier NCT04916600. Elsevier 2022-10-18 /pmc/articles/PMC9593273/ /pubmed/36303593 http://dx.doi.org/10.1016/j.conctc.2022.101018 Text en © 2022 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Greenwald, Mark K.
Ghosh, Samiran
Winston, Joe R.
A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence
title A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence
title_full A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence
title_fullStr A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence
title_full_unstemmed A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence
title_short A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence
title_sort randomized, sham-controlled, quintuple-blinded trial to evaluate the net device as an alternative to medication for promoting opioid abstinence
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593273/
https://www.ncbi.nlm.nih.gov/pubmed/36303593
http://dx.doi.org/10.1016/j.conctc.2022.101018
work_keys_str_mv AT greenwaldmarkk arandomizedshamcontrolledquintupleblindedtrialtoevaluatethenetdeviceasanalternativetomedicationforpromotingopioidabstinence
AT ghoshsamiran arandomizedshamcontrolledquintupleblindedtrialtoevaluatethenetdeviceasanalternativetomedicationforpromotingopioidabstinence
AT winstonjoer arandomizedshamcontrolledquintupleblindedtrialtoevaluatethenetdeviceasanalternativetomedicationforpromotingopioidabstinence
AT greenwaldmarkk randomizedshamcontrolledquintupleblindedtrialtoevaluatethenetdeviceasanalternativetomedicationforpromotingopioidabstinence
AT ghoshsamiran randomizedshamcontrolledquintupleblindedtrialtoevaluatethenetdeviceasanalternativetomedicationforpromotingopioidabstinence
AT winstonjoer randomizedshamcontrolledquintupleblindedtrialtoevaluatethenetdeviceasanalternativetomedicationforpromotingopioidabstinence